F. Hoffmann-La Roche AG said on Thursday its annual sales in 2025 reached 61.5 billion Swiss francs, climbing 7% in Swiss francs and 2% at constant exchange rates (CER) from the same period a year earlier. Sales in the pharmaceuticals division grew 9% at CER to 47.7 billion Swiss francs, while the diagnostics division sales rose 2% at CER year on year to 13.8 billion Swiss francs.
In the year, IFRS net income jumped 58% at CER to 13.8 billion Swiss francs while core diluted EPS rose 11% to 19.46 Swiss francs. For 2025, the pharmaceutical firm "expects an increase in Group sales in the mid single digit range (CER). Core earnings per share are targeted to develop in the high single digit range (CER)," the report showed.
"2025 was a strong year for Roche," Roche CEO Thomas Schinecker said, adding that "ten potential new medicines advanced into final-stage development."
https://breakingthenews.net/Article/Roche's-2025-sales-up-7-to-61.5B-Swiss-francs/65564571
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.